Latest News about MRK
Recent news which mentions MRK
   Price Over Earnings Overview: Merck & Co
   
  
  
  April 15, 2025
  From Benzinga
 
   Merck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery
   
  
  
  April 15, 2025
  From Benzinga
 
   Marjorie Taylor Greene Made Large Stock Purchases Ahead Of Trump's 90-Day Tariff Pause: Hakeem Jeffries Calls It 'Problematic'
   
  
  
  April 15, 2025
  From Benzinga
 
   Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
   
  
  
  April 11, 2025
  From Benzinga
 
   Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
   
  
  
  April 09, 2025
  From Benzinga
 
   Trump Hints At 'Major Tariff' On Imported Pharmaceuticals: Pfizer, Eli Lilly, Amgen And Other Stocks Tumble In Wednesday Pre-Market
   
  
  
  April 09, 2025
  From Benzinga
 From Motley Fool
 
   Why Health Care Select Sector SPDR Fund (XLV) Is Moving
   
  
  
  April 07, 2025
  From Benzinga
 
   Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
   
  
  
  April 04, 2025
  From Benzinga
 
   BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
   
  
  
  April 03, 2025
  From Benzinga
 
   2 Beaten-Down Stocks to Buy and Hold for a Decade
   
  
  
  April 02, 2025
  From Motley Fool
 
   Why Major Pharmaceutical Stocks Tumbled on Tuesday
   
  
  
  April 01, 2025
  From Motley Fool
 From Motley Fool
 
   Which Dow Jones Stock Is Cheaper, Amgen or Merck?
   
  
  
  March 28, 2025
  From Motley Fool
 
   Gamestop, FST Corp, Merck, UPS, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
   
  
  
  March 25, 2025
  From Benzinga
 
   Why Pharma and Biotech Stocks Got Thrashed on Tuesday
   
  
  
  March 25, 2025
  From Motley Fool
 
   Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment
   
  
  
  March 25, 2025
  From Benzinga
 From Benzinga
 From Benzinga
 
   2 Beaten-Down Stocks to Buy on the Dip
   
  
  
  March 22, 2025
  From Motley Fool
 From Benzinga
 
   Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types
   
  
  
  March 17, 2025
  From Benzinga
 From Motley Fool
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.